- Home
- HWBK vs TLSI Comparison
HWBK vs TLSI Comparison
Compare HWBK & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HWBK | TLSI |
|---|---|---|
| Founded | 1865 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.4M | 244.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HWBK | TLSI |
|---|---|---|
| Price | $34.46 | $7.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 11.3K | ★ 258.1K |
| Earning Date | 01-21-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 259.86 | N/A |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $77,904,000.00 | $40,207,000.00 |
| Revenue This Year | N/A | $55.06 |
| Revenue Next Year | N/A | $46.04 |
| P/E Ratio | $11.43 | ★ N/A |
| Revenue Growth | 45.83 | ★ 49.52 |
| 52 Week Low | $25.21 | $3.42 |
| 52 Week High | $36.49 | $7.70 |
Technical Indicators
Market Signals| Indicator | HWBK | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 69.74 |
| Support Level | $33.85 | $7.10 |
| Resistance Level | $36.25 | $7.53 |
| Average True Range (ATR) | 0.99 | 0.51 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.80 | 74.07 |
Price Performance
Historical ComparisonAbout HWBK Hawthorn Bancshares Inc.
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.